Google Cloud Expands Its Partnership With Ginkgo Bioworks For Two New AI-Tools Faster Drug Development

Tuesday, Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) announced two tools to streamline the drug development process for pharmaceutical and biotech companies.

Building on its partnership with Alphabet Inc’s (NASDAQ:GOOG) (NASDAQ:GOOGL) Google Cloud, Ginkgo introduced a protein large language model (LLM) and a model API, both designed to accelerate medicine development by leveraging AI and proprietary biological data.

These offerings aim to simplify and enhance how researchers and companies discover new therapeutics.

Researchers at Google DeepMind have developed AlphaFold 3, an new artificial intelligence (AI) model.

AlphaFold 3 can predict the structure and interactions of biological molecules. This includes proteins, DNA RNA, and small ...